Edwards Lifesciences Corp  

(Public, NYSE:EW)   Watch this stock  
Find more results for EDWARDS
-0.71 (-0.54%)
Jan 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 129.50 - 130.88
52 week 63.04 - 137.19
Open 130.62
Vol / Avg. 769,960.00/886,002.00
Mkt cap 13.87B
P/E 17.99
Div/yield     -
EPS 7.20
Shares 106.90M
Beta 0.61
Inst. own 90%
Feb 3, 2015
Q4 2014 Edwards Lifesciences Corp Earnings Call - 5:00PM EST - Add to calendar
Feb 3, 2015
Q4 2014 Edwards Lifesciences Corp Earnings Release - 4:00PM EST - Add to calendar
Dec 8, 2014
Edwards Lifesciences Corp Investor Conference
Nov 11, 2014
Edwards Lifesciences Corp at Credit Suisse Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 15.57% 19.15%
Operating margin 19.86% 25.19%
EBITD margin - 25.61%
Return on average assets 11.37% 15.84%
Return on average equity 19.17% 25.78%
Employees 8,600 -
CDP Score - -


One Edwards Way
IRVINE, CA 92614
United States - Map
+1-949-2502500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V.

Officers and directors

Michael A. Mussallem Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott B. Ullem Chief Financial Officer, Corporate Vice President
Age: 47
Bio & Compensation  - Reuters
Donald E. Bobo Jr. Corporate Vice President - Heart Valve Therapy
Age: 52
Bio & Compensation  - Reuters
Patrick B. Verguet Corporate Vice President, Europe, Middle East and Africa
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Huimin Wang M.D. Corporate Vice President, Japan, Asia Pacific
Age: 57
Bio & Compensation  - Reuters
Larry L. Wood Corporate Vice President - Transcatheter Valve Replacement
Age: 48
Bio & Compensation  - Reuters
Nicholas J. Valeriani Director
Age: 54
Bio & Compensation  - Reuters
Mike R. Bowlin Independent Director
Age: 71
Bio & Compensation  - Reuters
John T. Cardis Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert A. Ingram Independent Director
Age: 71
Bio & Compensation  - Reuters